2025

13-Nov-25

Trading update for the ten months ended 31 October 2025

06-Nov-25

Chief Executive Officer and Chief Financial Officer appointments

03-Nov-25

Convatec notes CMS payment plans for skin substitutes in the United States

27-Oct-25

Convatec announces Karim Bitar has passed away

27-Oct-25

Stigma, not condition, is the biggest barrier for 1 in 3 people living with chronic conditions, according to new Convatec research

08-Oct-25

Convatec announces closing of $500 Million 5.300% Senior Notes due 2035

02-Oct-25

Convatec announces pricing of $500 Million 5.300% Senior Notes due 2035

01-Oct-25

Convatec announces plans to invest more than $1 billion in R&D facilities – major expansions in the US and UK

29-Sep-25

Convatec announces offering of Senior Notes

22-Sep-25

Convatec secures regulatory approval for ConvaMatrix™ in UK and Europe, supporting more patients with pioneering skin substitute technology

02-Sep-25

Convatec strengthens Leadership Team to support growth

20-Aug-25

Convatec commences share buyback programme

04-Aug-25

Update regarding Chief Executive Officer

29-Jul-25

Interim results for the six months ended 30 June 2025

24-Jul-25

Convatec secures US and European regulatory clearance for Aquacel™ ConvaFiber™ wound care innovation

15-Jul-25

Convatec responds to CMS draft payment proposal for skin substitutes in the United States